A Phase 3 interventional study of Darolutamide (Nubeqa, BAY1841788) and Placebo in Prostatic Neoplasms, sponsored by Bayer. Completed at 131 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 7th largest by enrollment, is one of 9 that started in 2021, is one of 12 in phase 3, and was the 22nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
Region Stockholm · Sites in Sweden
Ages 18+ · Men only
By country, each count listing its studies:
darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 34 · Phase 3 14 · Phase 4 4
First in 2011; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 669 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 80 across the 59 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
75 studies in Prostatic Neoplasms by Bayer: 11 open now, 16 under way, 1 of them phase 3. Of 57 finished, 12 (21%) have results posted.
Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 7th largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2021, is one of 8 in phase 3, and was the 48th registered.
Bayer’s Prostatic Neoplasms studies by the year they started, since 2004.
9 of the studies testing darolutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT05762536Erasmus Medical CenterDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, from their registry updates:
Among Bayer’s 75 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy
Drug: Darolutamide (Nubeqa, BAY1841788) · Other: Androgen deprivation therapy (ADT)
Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy
Drug: Placebo · Other: Androgen deprivation therapy (ADT)
Coated tablet, oral administration
Coated tablet matching Darolutamide in appearance, oral administration
Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
Radiological Progression-free Survival (rPFS) Assessed by Central Review
rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria.
Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months
Overall Survival (OS)
Time from the date of randomization to the date of death from any cause.
Time frame: From randomization to the final analysis date, approximately 47 months
Time to Castration-Resistant Prostate Cancer (CRPC)
Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first).
Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to Initiation of Subsequent Anti-cancer Therapy
Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer.
Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to PSA Progression
Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level \<0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels \<0.50 ng/mL is requested at initial assessment.
Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months
PSA Undetectable Rates (<0.2 ng/mL)
Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values \<0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline.
Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to Pain Progression
Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale \[WPS\]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS \>0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization.
Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months
Number of Participants With Adverse Events as a Measure of Safety
An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.
Time frame: From start of study drug administration until 30 days after the last administration
Study was conducted at 133 centers in Europe/Rest of the world (ROW), Asia, and Latin America between 23-Feb-2021 (first participant first visit) and 23-Jan-2026 (last participant last visit).
| Milestone | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Started | 446 | 223 |
| Treated | 443 | 223 |
| Completed | 231 | 61 |
| Not completed | 215 | 162 |
| Withdrew: Adverse event | 30 | 22 |
| Withdrew: Death | 9 | 3 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Physician decision | 5 | 9 |
| Withdrew: Withdrawal by subject | 22 | 9 |
| Withdrew: Progressive disease | 124 | 102 |
| Withdrew: Subject decision | 13 | 13 |
| Withdrew: Required study drug interruption longer than allowed per protocol | 3 | 0 |
| Withdrew: Additional primary malignancy | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Other reason | 1 | 1 |
| Withdrew: Study drug never administered | 3 | 0 |
| Milestone | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Started | 231 | 60 |
| Completed | 231 | 60 |
| Not completed | 0 | 0 |
rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria.
| Months | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Radiological Progression-free Survival (rPFS) Assessed by Central Review | NA (NA to NA) | 25.0 (19.0 to NA) |
Time from the date of randomization to the date of death from any cause.
| Months | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| At primary completion cut-off | NA (NA to NA) | NA (33.8 to NA) |
| At final analysis cut-off | NA (NA to NA) | NA (NA to NA) |
Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first).
| Months | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Time to Castration-Resistant Prostate Cancer (CRPC) | NA (NA to NA) | 13.8 (12.0 to 16.8) |
Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer.
| Months | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Time to Initiation of Subsequent Anti-cancer Therapy | NA (NA to NA) | NA (27.7 to NA) |
Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level \<0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels \<0.50 ng/mL is requested at initial assessment.
| Months | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Time to PSA Progression | NA (NA to NA) | 16.8 (13.9 to 20.1) |
Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values \<0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline.
| Percentage of participants | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| PSA Undetectable Rates (<0.2 ng/mL) | 62.6 (57.8 to 67.2) | 18.5 (13.5 to 24.4) |
Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale \[WPS\]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS \>0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization.
| Months | Darolutamide+ADT | Placebo+ADT |
|---|---|---|
| Time to Pain Progression | NA (NA to NA) | 29.9 (29.7 to NA) |
An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.
| Participants | Darolutamide (DB) | Darolutamide (DB + OL) | Placebo (DB) | Placebo - Darolutamide (CO) |
|---|---|---|---|---|
| Any TEAE | 407 | 409 | 199 | 30 |
| Any TESAE | 109 | 126 | 52 | 8 |
| Any study drug-related TEAE | 147 | 154 | 64 | 8 |
Collected over From start of study drug administration until 30 days after the last administration. All-cause mortality death events at any time during the study (approximately 59 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Darolutamide (DB) | 123/446 (27.6%) | 109/446 (24.4%) | 329/446 (73.8%) |
| Darolutamide (DB + OL) | 126/446 (28.3%) | 126/446 (28.3%) | 341/446 (76.5%) |
| Placebo (DB) | 76/220 (34.5%) | 52/220 (23.6%) | 156/220 (70.9%) |
| Placebo - Darolutamide (CO) | 2/59 (3.4%) | 8/59 (13.6%) | 14/59 (23.7%) |
| Event | Darolutamide (DB) | Darolutamide (DB + OL) | Placebo (DB) | Placebo - Darolutamide (CO) |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 8/446 | 8/446 | 1/220 | 0/59 |
| Myocardial infarctionCardiac disorders | 3/446 | 3/446 | 0/220 | 1/59 |
| CellulitisInfections and infestations | 1/446 | 1/446 | 1/220 | 1/59 |
| InfectionInfections and infestations | 1/446 | 1/446 | 0/220 | 1/59 |
| Liver abscessInfections and infestations | 1/446 | 1/446 | 0/220 | 1/59 |
| FallInjury, poisoning and procedural complications | 0/446 | 0/446 | 1/220 | 1/59 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/446 | 0/446 | 0/220 | 1/59 |
| Intestinal obstructionGastrointestinal disorders | 0/446 | 0/446 | 0/220 | 1/59 |
| AppendicitisInfections and infestations | 0/446 | 0/446 | 0/220 | 1/59 |
| PneumoniaInfections and infestations | 6/446 | 7/446 | 2/220 | 0/59 |
| Event | Darolutamide (DB) | Darolutamide (DB + OL) | Placebo (DB) | Placebo - Darolutamide (CO) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 94/446 | 106/446 | 37/220 | 4/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 57/446 | 61/446 | 26/220 | 0/59 |
| Bone painMusculoskeletal and connective tissue disorders | 31/446 | 31/446 | 27/220 | 0/59 |
| Urinary tract infectionInfections and infestations | 49/446 | 50/446 | 19/220 | 0/59 |
| ConstipationGastrointestinal disorders | 48/446 | 49/446 | 16/220 | 0/59 |
| Back painMusculoskeletal and connective tissue disorders | 46/446 | 48/446 | 22/220 | 0/59 |
| Aspartate aminotransferase increasedInvestigations | 45/446 | 46/446 | 17/220 | 1/59 |
| HypertensionVascular disorders | 39/446 | 44/446 | 19/220 | 1/59 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 41/446 | 43/446 | 19/220 | 1/59 |
| Alanine aminotransferase increasedInvestigations | 40/446 | 42/446 | 19/220 | 1/59 |
| Age, Continuous(Years) | Darolutamide+ADT | Placebo+ADT | Total |
|---|---|---|---|
| Mean | 69.6 ± 8.8 | 69.2 ± 8.9 | 69.5 ± 8.8 |
| Sex: Female, Male(Participants) | Darolutamide+ADT | Placebo+ADT | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 446 | 223 | 669 |
| Ethnicity (NIH/OMB)(Participants) | Darolutamide+ADT | Placebo+ADT | Total |
|---|---|---|---|
| Hispanic or Latino | 104 | 58 | 162 |
| Not Hispanic or Latino | 334 | 157 | 491 |
| Unknown or Not Reported | 8 | 8 | 16 |
| Race/Ethnicity, Customized(Participants) | Darolutamide+ADT | Placebo+ADT | Total |
|---|---|---|---|
| White | 251 | 125 | 376 |
| Black or African American | 41 | 24 | 65 |
| Asian | 144 | 65 | 209 |
| Other | 10 | 9 | 19 |
Showing the first 100 of 131 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Feb 2021 to primary completion in Jun 2024, 39 months.
Results were first posted in Aug 2025, 1 year 2 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 39 months is close to that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darolutamide